We are pleased to announce the appointment of Nagihan ŞENGÜL KARPUZ to Board of Directors

VSY Biotechnology, leading ophthalmic and orthopedic medical device and biotechnology company, announces the appointment of Nagihan ŞENGÜL KARPUZ to the company’s Board of Directors.

Nagihan Şengül Karpuz has been appointed Board Member of VSY Biotechnology. She began her carrier at E&Y and has spent most of her career at Yıldız Holding, working in various areas related to tax compliance,

Enova® is Available Now in C Haptic Model

VSY Biotechnology announces the launch of the Enova® C Haptic Model IOL. Enova® is the first and only 100% Glistening-Free, Dry-Packed hydrophobic acrylic IOL. Moreover, no warming or special conditioning is required before surgery!

VSY Biotechnology Launches Enova® 100% Glistening-Free Hydrophobic Acrylic IOL in C Haptic Model. The unique composition of Enova® material allows uniform hydration of specific sites to have controlled water uptake and resistance to glistening formation.

VSY Biotechnology GmbH Honored as 2021 MDEA Finalist

The 2021 Medical Design Excellence Awards Finalists have been announced! VSY Biotechnology is excited to share that VSY Biotechnology’s Trifocal IOL with Sinusoidal Vision Technology: Acriva Trinova is listed among the finalists of the Medical Design Excellence Awards competition. 

Leinfelden – Echterdingen, Germany April 21, 2021, ­ VSY Biotechnology GmbH, an innovation-driven company with its progressive R&D activities in ophthalmology,

VSY Biotechnology Appoints Can Ongen to Board of Directors

Germany, March 23, 2021 – VSY Biotechnology, leading ophthalmic and orthopedic medical device and biotechnology company, announces the appointment of seasoned executive leader Can Ongen to the company’s Board of Directors. In this role, Can Ongen will also lead VSY Biotechnology’s sales and marketing activities with a view to further strengthening the company’s position worldwide.

VSY Biotechnology GmbH, Signs Agreement with WAKAMOTO PHARMACEUTICAL CO., LTD. on Intraocular Lens Products

Leinfelden – Echterdingen, Germany March 19, 2021, ­ VSY Biotechnology GmbH, an innovation-driven company with its progressive R&D activities in ophthalmology, visco supplementation in orthopedy and medical esthetics, announced today an agreement with WAKAMOTO PHARMACEUTICAL CO., LTD. (hereinafter refer to “WAKAMOTO PHARMACEUTICAL“) to provide new treatments for cataract surgeries in Japan. The agreement includes a licensing arrangement with WAKAMOTO PHARMACEUTICAL to develop and launch intraocular lenses (IOLs) in Japan.

Supreme Harmony” For OVD Needs

VSY Biotechnology Introduces Protectalon DUO Kit, demonstrating commitment to Ophthalmic Surgery! Eye Care Professionals meet their OVD needs at different stages of cataract surgery with a single kit. It is available now for safe, fast and smooth surgery!


  • Dual Pack containing one unit cohesive and one unit dispersive OVDs
  • High Filling Volume (1.1 ml Cohesive + 1.1 ml Dispersive)

VSY Biotechnology GmbH,

VSY Biotechnology Announce The Winners Of 2020 Ophthalmology Star Awards (OSA)

VSY Biotechnology GmbH, an innovation-driven company with progressive R&D activities in ophthalmology, has announced the winners of the 2020 Ophthalmology Star Awards. This year’s “Ophthalmology Star Award” is dedicated to Dr. Li Wenliang, an ophthalmologist who was the first to raise the alarm about COVID-19.

Ophthalmologists applied for the contest with their articles until September 18,

VSY Biotechnology Launches Enova, the First 100% Glistening Free

Hydrophobic Acrylic IOL that does not Require Pre-hydration and Storage in Saline Solution!

VSY Biotechnology announces Enova, the first 100% glistening-free hydrophobic acrylic IOL that requires neither pre-hydration nor storage in saline. Enova is packaged dry and has excellent optical and mechanical properties.

Leinfelden-Echterdingen, Germany July 22, 2020 ­- VSY Biotechnology GmbH,

Willkommen in Deutschland! VSY Biotechnology moves its HQ to Germany

VSY Biotechnology announced that it is moving its headquarters from the Netherlands to Germany. VSY Biotechnology GmbH will be the company’s new headquarters.

VSY Biotechnology commenced operations in the late 90s. Since then, the company has achieved several milestones on the way to becoming a global player in the innovation-driven medical device sector.

Countdown to the Ophthalmology Star Awards

Applications for this year’s Ophthalmology Star Awards (OSA), organized annually by VSY Biotechnology, will continue until July 15, 2020.

As part of the Ophthalmology Star Awards (OSA), articles by ophthalmologists published in English since January 2019 are being evaluated by an international jury. Ophthalmologists can apply for the contest until July 15, 2020,

Dr. Fatih Ergin, CEO of VSY Biotechnology: “The 21st century has started just now”

Dr. Fatih Ergin, CEO of VSY Biotechnology, stated that traditional roles and models worldwide will be completely transformed by the traumatic impact of the coronavirus and added that “the 21st century has just started now.”

Dr. Fatih Ergin, CEO of VSY Biotechnology, stated that the company anticipates that the coronavirus pandemic, which has led to many losses of life,

Acriva Trinova Has Been Registered by The European Patent Office

World’s First and Only Sinusoidal Trifocal Optical Designed Intraocular Lens Acriva Trinova has Been Registered by the Euroepean Patent Office

European Patent Office (EPO) has issued the decision of appropriate for patent for world’s first and only intraocular lens produced with Sinusoidal Vision Technology (SVT) by VSY Biotechnology.

In the year 2018,

VSY Biotechnology Picks the Stars of Ophthalmology

With its booth, and scientific and social events, VSY Biotechnology was the center of attention at the 37th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), the world’s premier ophthalmology event. VSY Biotechnology organized the Stars of Ophthalmology Award Ceremony, presented the awards to the finalists, and attracted a great deal of attention in Paris on September 14–18,

VSY Biotechnology increases its speed in Europe with a new logistics center and online ordering system!

VSY Biotechnology invests in a faster and more efficient supply chain in Europe.

VSY Biotechnology, with head offices in the Netherlands, Spain, and Germany, has strengthened its network with new logistics centers in Europe. The company opened a new logistics center in Germany on 20 August 2019. A new online ordering system was commissioned at the beginning of the year.

VSY Biotechnology’s invention has been registered by the European Patent Institute

VSY Biotechnology’s invention, the Rotaryjet Preloaded Injector containing an accessory system for the storage and injection of an intraocular lens, has been registered by the European Patent Institute (EPI). This newly patented technology minimises the use of viscoelastic material in intraocular lens implantation and provides ultimate ease of use.

The Rotaryjet Preloaded Injector,

Halo and glare? Not a problem anymore!

ESCRS Board Member Prof.Dr. Ewa Mrukwa-Kominek told that Acriva Trinova implanted patients do not experience glare and halos and have very sharp visual equity.

Halos are bright circles that surround a light source, like headlights. Glare is light that enters your eye and interferes with your vision. These vision problems can be very disturbing even disabling after a cataract surgery.

VSY Biotechnology Calls for “Ophthalmology Star Awards”

VSY Biotechnology is now accepting applications for the Ophthalmology Star Awards.

The Stars of Ophthalmology will be selected among the applicants who have a scientific article published in an ophthalmology journal since January 2018.

The articles are required to be authored in English and already published in order to be eligible for the Ophthalmology Star Awards.

VSY Biotechnology Meets with European Ophthalmologists

Offering its product scope to more than 60 countries from Germany to Japan, Brazil to South Korea, Spain to South Africa, VSY Biotechnology is still going on to take part in most of the world’s most important congresses. VSY Biotechnology participated in DOC 2019 which was held in Germany, Nuremberg Convention Center between May 23-25,

A Novel Approach to Trifocal IOLs: Sinusoidal Optic Design

VSY Biotechnology announced the launch of its new sinusoidal trifocal IOL, AcrivaUD Trinova, at the 2017 European Society of Cataract and Refractive Surgeons meeting in Portugal. VSY has also confirmed that its patent applications have been submitted around the world, and its product CE mark was received in October 2017. AcrivaUD Trinova is the world’s first and only sinusoidal trifocal IOL manufactured with Sinusoidal Vision Technology (SVT).

VSY Biotechnology BV and Carl Zeiss Meditec AG Settled Their Legal Disputes

VSY Biotechnology BV and Carl Zeiss Meditec AG jointly announced that both companies resolved their legal and patent disputes with respect to Tri-ED 611. The companies agreed not to disclose the terms of the settlement.

“With Technological Developments Eyesight is Enhanced”

CEO Özge Altunbaş Göktekin of VSY Biotechnology, a significant global company in the field of ophthalmology, gave us valuable information on cataract disease and solutions provided by the company’s new trifocal intraocular lenses. Altunbaş said: “With the help of the trifocal intraocular lenses we developed, we can offer a solution for both cataracts and eye defects.

“Management Ideas and Approaches are Transformed in Companies”

VSY Biotechnology CEO Özge Altunbaş Göktekin stated that extraordinary developments observed recently in science and communication technologies have caused a transformation in the management approaches adopted by companies and added: “With technological advances transforming management ideas and approaches in enterprises, managers and employees now feel obliged to adopt a proactive, creative, and responsible role in their organization.”

We addressed our questions to VSY Biotechnology CEO Özge Altunbaş Göktekin about changing management approaches. 

The World’s First and Only Sinusoidal-Formed Trifocal Intraocular Lens

Presented at the ESCRS Satellite Symposium

VSY Biotechnology Offers “A New Approach to Trifocal Intraocular Lens Technology”

The  European Cataract and Refractive Surgery Association held their 36th annual meeting from September 22nd to 26th, 2018. This meeting included an examination of trifocal intraocular lenses (IOLs)  produced with advanced technology. Specifically, VSY Biotechnology shared the features and clinical results of AcrivaUD Trinova IOLs that they developed after extensive R&D studies.

Innovations in Cataract and Refractive Science Will Come to Light in ESCRS

The 36th ESCRS Congress will be organized by the European Cataract and Refractive Surgery Association in Wien/Austria on 22-26 September 2018. The Congress will enjoy the participation of international companies specialized in eye health who will present the latest innovations in the science of ophthalmology. While more than 10.000 visitors from all around the world are expected to attend the congress,

VSY Biotechnology Took Out a Patent for Two Important Inventions in the Area of Eye Health

VSY Biotechnology took out a patent for a “Rotaryjet Preloaded Injector” enabling the easy, quick, and safe injection and implantation of intra-ocular lenses during cataract operations. The firm also became the owner of a patent for its new packing of intra-ocular lenses produced with biocompatible material that has strong sterilization characteristics.

In the “Rotaryjet Preloaded Injector,” which was invented and patented by VSY Biotechnology,

Intermediate Solution by Intra-articular Injection Without Surgery

Osteoarthritis causes reduced movement and pain due to the disruption of the cartilaginous structures on the joint surface. New solutions offer treatments without surgery. One of the most important treatments recently accepted all over the world is intra-articular injection, which slows the progression of osteoarthritis.

Knee, hip, ankle, finger, and spinal joints are the sites in the body most commonly affected by osteoarthritis,

Trinova lenses cease eyeglasses need: VSY Biotechnology

Over past eight years, 3 million people have been implanted VSY Biotechnology intraocular lenses through cataract surgeries, says CEO Ozge Altunbas Goktekin

Acriva Trinova lenses not only manage cataract, but also provides continuous sight on near, mid, far and intermediate ranges, CEO of the Netherlands based company VSY Biotechnology said.


Acriva Trinova Trifocal

VSY Biotechnology announced the launch of its Acriva Trinova Trifocal IOL (Figure 4) at the meeting. The Acriva Trinova is manufactured with VSY’s Seamless Vision Technology, a patent-pending technique that produces an optical surface with no sharp edges. The concept provides a continuous range of vision and helps to reduce halos and scattered light, according to VSY.

VSY Biotechnology Intraocular Lenses Give Clear Vision to 3 Million People

VSY Biotechnology Chairman Ercan Varlıbaş, M.D., visits the ASCRS Annual Meeting in Washington. Each year his company exports cataract lenses worth millions of dollars, VSY Biotechnology intraocular lenses have helped 3 million of people with eye problems, around the world to achieve clear vision.

Dr. Ercan Varlıbaş, Chairman of VSY Biotechnology, recently visited the American Cataract and Refractive Surgery Association (ASCRS) Annual Meeting and Scientific Session in Washington,